21:25 , May 1, 2019 |  BC Extra  |  Company News

Management tracks: Gilead, bluebird, Apollomics

Gilead Sciences Inc. (NASDAQ:GILD) said Robin Washington will retire as EVP and CFO, effective March 1, 2020. Washington, who joined Gilead in 2008, will continue in her role while the company identifies a successor. Gene...
23:41 , Apr 19, 2019 |  BioCentury  |  Product Development

Companies poised to take Chinese checkpoints global

At least three companies are well positioned to answer FDA Oncology chief Richard Pazdur’s call to bring Chinese PD-1/PD-L1 inhibitors to the U.S. to compete on price. Two Chinese drugmakers and one U.S. company globally...
23:44 , Jan 23, 2019 |  BC Extra  |  Company News

Management tracks: Cabaletta, Sage, MyoKardia

Autoimmune cell therapy company Cabaletta Bio Inc. (Radnor, Pa.) hired Anup Marda as CFO. He was VP and head of global corporate financial planning and analysis at Bristol-Myers Squibb Co. (NYSE:BMY). Marda succeeds interim CFO...
17:54 , Jan 11, 2019 |  BC Week In Review  |  Financial News

CBT rebrands as Apollomics, raises $100M series B

CBT Pharmaceuticals Inc. has rebranded as Apollomics Inc. (Foster City, Calif.) and raised $100 million in a series B round to advance the development of its immunotherapy and targeted cancer therapy programs globally. The company...
12:51 , Jan 7, 2019 |  BC Extra  |  Financial News

CBT rebrands as Apollomics, raises $100M series B

CBT Pharmaceuticals Inc. has rebranded as Apollomics Inc. (Foster City, Calif.) and raised $100 million in a series B round to advance the development of its immunotherapy and targeted cancer therapy programs globally. The company...
20:02 , Dec 14, 2018 |  BC Week In Review  |  Company News

Strata to screen patients for Phase I of CBT's CBT-101

CBT Pharmaceuticals Inc. (Pleasanton, Calif.) and Strata Oncology Inc. (Ann Arbor, Mich.) partnered to enroll patients in a Phase I trial evaluating CBT-101 to treat c-Met receptor tyrosine kinase (c-MET; MET; HGFR; c-Met proto-oncogene)-dysregulated malignancies....
21:39 , Nov 30, 2018 |  BC Week In Review  |  Company News

CBT, Bossan partner for combination trials

CBT Pharmaceuticals Inc. (Pleasanton, Calif.) gained exclusive, worldwide rights to develop and commercialize EGFR inhibitor ES-072 outside of Greater China from Zhejiang Bossan Pharmaceutical Co. Ltd. (Hangzhou, China). CBT and Bossan will jointly develop and...
22:32 , Aug 16, 2018 |  BC Extra  |  Company News

Management tracks: Achillion, Navidea

Rare disease company Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) hired Anthony Gibney as EVP and CBO. He was managing director and co-head of the biotechnology investment banking team at Leerink Partners. Immunotherapy company Navidea Biopharmaceuticals Inc. (NYSE-A:NAVB;...
20:10 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Autism Mouse studies suggest inhibiting MAPK could help treat autism. In a mouse model of autism, subcutaneous injection with a tool compound MAPK inhibitor decreased numbers of cortical progenitor cells and behavioral deficits and...
18:18 , Mar 30, 2018 |  BC Week In Review  |  Company News

CBT gets rights to CTLA-4 antibody

Crown Bioscience International Inc. (TPEx:6554) granted CBT Pharmaceuticals Inc. (Pleasanton, Calif.) exclusive, worldwide rights to CBT-509, a human mAb against cytotoxic T-lymphocyte associated protein 4 (CTLA-4; CTLA4; CD152). Crown is eligible for up to $47...